Jennifer LeMessurier1, Gregory Traversy1, Olivia Varsaneux1, Makenzie Weekes1, Marc T Avey1, Oscar Niragira1, Robert Gervais1, Gordon Guyatt1, Rachel Rodin2. 1. Centre for Communicable Diseases and Infection Control (Traversy, Varsaneux, Weekes, Avey, Niragira, Gervais, Rodin), Public Health Agency of Canada; Department of Family Medicine (LeMessurier) and School of Epidemiology and Public Health (LeMessurier), University of Ottawa, Ottawa, Ont.; Department of Health Research Methods, Evidence, and Impact (Guyatt), McMaster University, Hamilton, Ont. 2. Centre for Communicable Diseases and Infection Control (Traversy, Varsaneux, Weekes, Avey, Niragira, Gervais, Rodin), Public Health Agency of Canada; Department of Family Medicine (LeMessurier) and School of Epidemiology and Public Health (LeMessurier), University of Ottawa, Ottawa, Ont.; Department of Health Research Methods, Evidence, and Impact (Guyatt), McMaster University, Hamilton, Ont. rachel.rodin@canada.ca.
Abstract
BACKGROUND: The Public Health Agency of Canada reviewed sexual transmission of HIV between serodiscordant partners to support examination of the criminal justice system response to HIV nondisclosure by the Department of Justice of Canada. We sought to determine HIV transmission risk when an HIV-positive partner takes antiretroviral therapy, has a suppressed viral load or uses condoms. METHODS: We conducted an overview and systematic review update by searching MEDLINE and other databases (Jan. 1, 2007, to Mar. 13, 2017; and Nov. 1, 2012, to Apr. 27, 2017, respectively). We considered reviews and studies about absolute risk of sexual transmission of HIV between serodiscordant partners to be eligible for inclusion. We used A Measurement Tool to Assess Systematic Reviews (AMSTAR) for review quality, Quality in Prognosis Studies (QUIPS) instrument for study risk of bias and then the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to assess the quality of evidence across studies. We calculated HIV incidence per 100 person-years with 95% confidence intervals (CIs). We assigned risk categories according to potential for and evidence of HIV transmission. RESULTS: We identified 12 reviews. We selected 1 review to estimate risk of HIV transmission for condom use without antiretroviral therapy (1.14 transmissions/100 person-years, 95% CI 0.56-2.04; low risk). We identified 11 studies with 23 transmissions over 10 511 person-years with antiretroviral therapy (0.22 transmissions/ 100 person-years, 95% CI 0.14-0.33; low risk). We found no transmissions with antiretroviral therapy and a viral load of less than 200 copies/mL across consecutive measurements 4 to 6 months apart (0.00 transmissions/100 person-years, 95% CI 0.00-0.28; negligible risk regardless of condom use). INTERPRETATION: Based on high-quality evidence, there is a negligible risk of sexual transmission of HIV when an HIV-positive sex partner adheres to antiretroviral therapy and maintains a suppressed viral load of less than 200 copies/mL measured every 4 to 6 months. Sexual transmissions of HIV have occurred when viral load was more than 200 copies/mL with antiretroviral therapy or condoms alone were used, although the risk remains low. These findings will help to support patient and clinician decision-making, affect public health case management and contact tracing, and inform justice system responses to HIV nondisclosure.
BACKGROUND: The Public Health Agency of Canada reviewed sexual transmission of HIV between serodiscordant partners to support examination of the criminal justice system response to HIV nondisclosure by the Department of Justice of Canada. We sought to determine HIV transmission risk when an HIV-positive partner takes antiretroviral therapy, has a suppressed viral load or uses condoms. METHODS: We conducted an overview and systematic review update by searching MEDLINE and other databases (Jan. 1, 2007, to Mar. 13, 2017; and Nov. 1, 2012, to Apr. 27, 2017, respectively). We considered reviews and studies about absolute risk of sexual transmission of HIV between serodiscordant partners to be eligible for inclusion. We used A Measurement Tool to Assess Systematic Reviews (AMSTAR) for review quality, Quality in Prognosis Studies (QUIPS) instrument for study risk of bias and then the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach to assess the quality of evidence across studies. We calculated HIV incidence per 100 person-years with 95% confidence intervals (CIs). We assigned risk categories according to potential for and evidence of HIV transmission. RESULTS: We identified 12 reviews. We selected 1 review to estimate risk of HIV transmission for condom use without antiretroviral therapy (1.14 transmissions/100 person-years, 95% CI 0.56-2.04; low risk). We identified 11 studies with 23 transmissions over 10 511 person-years with antiretroviral therapy (0.22 transmissions/ 100 person-years, 95% CI 0.14-0.33; low risk). We found no transmissions with antiretroviral therapy and a viral load of less than 200 copies/mL across consecutive measurements 4 to 6 months apart (0.00 transmissions/100 person-years, 95% CI 0.00-0.28; negligible risk regardless of condom use). INTERPRETATION: Based on high-quality evidence, there is a negligible risk of sexual transmission of HIV when an HIV-positive sex partner adheres to antiretroviral therapy and maintains a suppressed viral load of less than 200 copies/mL measured every 4 to 6 months. Sexual transmissions of HIV have occurred when viral load was more than 200 copies/mL with antiretroviral therapy or condoms alone were used, although the risk remains low. These findings will help to support patient and clinician decision-making, affect public health case management and contact tracing, and inform justice system responses to HIV nondisclosure.
Authors: Jessica M Fogel; Lei Wang; Teresa L Parsons; San-San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O Mudhune; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R Santos; Kenneth H Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N Bumpus; Craig W Hendrix; Myron S Cohen; Susan H Eshleman Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Maria J Wawer; Ronald H Gray; Nelson K Sewankambo; David Serwadda; Xianbin Li; Oliver Laeyendecker; Noah Kiwanuka; Godfrey Kigozi; Mohammed Kiddugavu; Thomas Lutalo; Fred Nalugoda; Fred Wabwire-Mangen; Mary P Meehan; Thomas C Quinn Journal: J Infect Dis Date: 2005-03-30 Impact factor: 5.226
Authors: Susan H Eshleman; Sarah E Hudelson; Andrew D Redd; Ronald Swanstrom; San-San Ou; Xinyi Cindy Zhang; Li-Hua Ping; Estelle Piwowar-Manning; Stephen F Porcella; Matthew F Sievers; Craig A Martens; Daniel Bruno; Elena Dukhovlinova; Marybeth McCauley; Theresa Gamble; Jessica M Fogel; Devin Sabin; Thomas C Quinn; Laurence Gunde; Madalitso Maliwichi; Nehemiah Nhando; Victor Akelo; Sikhulile Moyo; Ravindre Panchia; Nagalingeswaran Kumarasamy; Nuntisa Chotirosniramit; Marineide Gonçalves de Melo; Jose Pilotto; Beatriz Grinsztejn; Kenneth Mayer; Ying Q Chen; James P Hughes; Myron S Cohen Journal: J Acquir Immune Defic Syndr Date: 2017-01-01 Impact factor: 3.731
Authors: Rose Apondi; Rebecca Bunnell; John Paul Ekwaru; David Moore; Stevens Bechange; Kenneth Khana; Rachel King; James Campbell; Jordan Tappero; Jonathan Mermin Journal: AIDS Date: 2011-06-19 Impact factor: 4.177
Authors: Josephine Birungi; Jeong Eun Min; Katherine A Muldoon; Pontiano Kaleebu; Rachel King; Sarah Khanakwa; Maureen Nyonyintono; YaLin Chen; Edward J Mills; Fred Lyagoba; Manon Ragonnet-Cronin; Jonathan Wangisi; Lillian Lourenco; David M Moore Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240
Authors: Na He; Song Duan; Yingying Ding; Keming Rou; Jennifer M McGoogan; Manhong Jia; Yuecheng Yang; Jibao Wang; Julio S G Montaner; Zunyou Wu Journal: PLoS One Date: 2013-11-13 Impact factor: 3.240
Authors: Eric Abella Roth; Zishan Cui; Heather L Armstrong; Ashleigh J Rich; Nathan J Lachowsky; Paul Sereda; Kiffer G Card; Nic Bacani; David Moore; Robert Hogg Journal: J Bisex Date: 2021-10-14
Authors: Benjamin P Sullivan; Yu-Shan Chou; Andrew T Bender; Coleman D Martin; Zoe G Kaputa; Hugh March; Minyung Song; Jonathan D Posner Journal: Lab Chip Date: 2022-06-14 Impact factor: 7.517
Authors: Walid G El-Nahal; Nicola M Shen; Jeanne C Keruly; Joyce L Jones; Anthony T Fojo; Yukari C Manabe; Richard D Moore; Kelly A Gebo; Geetanjali Chander; Catherine R Lesko Journal: J Acquir Immune Defic Syndr Date: 2022-09-01 Impact factor: 3.771
Authors: Erika L Crable; Thomas R Blue; Michelle McKenzie; Josiah D Rich; Michael S Gordon Journal: J Acquir Immune Defic Syndr Date: 2021-05-01 Impact factor: 3.771
Authors: Ignacio Rodríguez-Izquierdo; Daniel Sepúlveda-Crespo; Jose María Lasso; Salvador Resino; Ma Ángeles Muñoz-Fernández Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2022-01-12
Authors: Suzan M Walters; Amy Braksmajer; Bethany Coston; Irene Yoon; Christian Grov; Martin J Downing; Richard Teran; Sabina Hirshfield Journal: Arch Sex Behav Date: 2020-01-21
Authors: Karen Diepstra; Haidong Lu; Kathleen A McManus; Elizabeth T Rogawski McQuade; Anne G Rhodes; Daniel Westreich Journal: AIDS Date: 2020-09-01 Impact factor: 4.632